Fosphenytoin sodium

CLINICAL USE

Control of status epilepticus Seizures associated with neurosurgery or head injury when oral phenytoin is not possible

DOSE IN NORMAL RENAL FUNCTION

Status epilepticus: Treatment: 20 mg PE/kg (loading dose) —by

IV infusion

Maintenance: 4–5 mg PE/kg daily in —1–2 divided dosesProphylaxis or treatment of seizures: 10– 15 mg PE/kg by

IV infusion

; then convert to phenytoin or 4–5 mg PE/kg daily in 1–2 divided doses

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :406.2

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :95–99

%Excreted unchanged in urine &nbsp &nbsp : 1–5

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :4.3–10.8 litres

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :18.9 (IV), 41.2 (IM)/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Reduce dose or rate by 10–25% and monitor carefully (except for status epilepticus)

10 to 20 &nbsp &nbsp : Reduce dose or rate by 10–25% and monitor carefully (except for status epilepticus)

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Reduce dose or rate by 10–25% and monitor carefully (except for status epilepticus)

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as for GFR <10 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as for GFR <10 mL/min

HDF/high flux &nbsp :Unlikely to be dialysed. Dose as for GFR <10 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as for GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Analgesics: enhanced effect with NSAIDs; metabolism of methadone accelerated

Anti-arrhythmics: increased concentration with amiodarone; concentration of disopyramide and mexiletine reduced

Antibacterials: level increased by clarithromycin, chloramphenicol, isoniazid, metronidazole, co-trimoxazole and trimethoprim (+ antifolate effect); concentration increased or decreased by ciprofloxacin; concentration of doxycycline and telithromycin reduced; concentration reduced by rifampicin

Anticoagulants: increased metabolism of coumarins (reduced effect but also reports of enhancement)

Antidepressants: MAOIs, SSRIs and tricyclics antagonise anticonvulsant effect, concentration increased by fluoxetine and fluvoxamine; reduced concentration of mianserin, mirtazepine, paroxetine and possibly tricyclics; concentration reduced by St John’s wort – avoid

Anti-epileptics: concentration of both drugs reduced with carbamazepine; concentration may also be increased by carbamazepine, ethosuximide, oxcarbazepine and topiramate; possibly reduced concentration of ethosuximide, active oxcarbazepine metabolite, primidone (but active metabolite increased), topiramate and valproate; reduced concentration of lamotrigine, tiagabine and zonisamide; primidone and valproate may alter concentration; concentration reduced by vigabatrin

Antifungals: reduced concentration of ketoconazole, itraconazole, posaconazole, voriconazole and possibly caspofungin – avoid with itraconazole, increase voriconazole dose and possibly caspofungin; levels increased by fluconazole, miconazole and voriconazole

Antimalarials: antagonise anticonvulsant effect; increased antifolate effect with pyrimethamine

Antipsychotics: antagonise anticonvulsant effect; aripiprazole concentration possibly reduced – increase aripiprazole dose; Fosphenytoin sodium.fOSPHeNYtOIN SODIUM 335metabolism of clozapine, quetiapine and sertindole increased

Calcium-channel blockers: levels increased by diltiazem; reduced concentration of diltiazem, felodipine, isradipine, nisoldipine and verapamil and possibly dihydropyridines, nicardipine and nifedipine

Ciclosporin: reduced ciclosporin levels Corticosteroids: metabolism accelerated (effect reduced)Cytotoxics: metabolism inhibited by fluorouracil; increased antifolate effect with methotrexate; reduced phenytoin absorption; reduced concentration of busulfan, etoposide and imatinib – avoid with imatinibDisulfiram: levels of phenytoin increased

Diuretics: concentration of eplerenone reduced – avoid concomitant use; increased risk of osteomalacia with carbonic anhydrase inhibitors; antagonises effect of furosemideOestrogens and progestogens: metabolism increased (reduced contraceptive effect)Sulfinpyrazone: concentration increased by sulfinpyrazone

Tacrolimus: reduced tacrolimus levels Theophylline: concentration of both drugs reduced

Ulcer-healing drugs: metabolism inhibited by cimetidine; absorption reduced by sucralfate; enhanced effect with esomeprazole and omeprazole

ADMINISTRATION

Reconstition

–

Route

IV, IM

Rate of Administration

Status epilepticus : 100–150 mg PE/min Treatment and prophylaxis of seizures: 50–100 mg PE/min

Comments

Dilute further when using for

IV infusion

with sodium chloride 0.9% or glucose 5% to 1.5–25 mg PE/mL

OTHER INFORMATION

75 mg of fosphenytoin sodium is equivalent to 50 mg of phenytoin0.037 mmol of phosphate/mg of fosphenytoinDecreased protein binding in renal failure Monitor ECG, BP and respiratory function during infusionWhen substituting IV, IM use same dose and frequency as for oral phenytoin, administer at a rate of 50–100 mg PE/minMay increase blood glucose in diabetic patientsSome is dialysed out, as not all PE is protein-boundHalf-life of fosphenytoin to phenytoin is 15 minutes; more rapid in renal failure due to reduced protein binding.

Tags: post-by-auto-php